Versartis, Inc. IPO Research Information

Versartis, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Versartis, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Versartis, Inc.	VSAR - NASDAQ	$16.00-$19.00	$21.00	$28.00	6 million	3/21/2014
Underwriter(s): Morgan Stanley, Citigroup
Co-Manager(s): Cowen & Co., Canaccord Genuity
Industry: Health Care
Filing(s): Filed 2014-02-18 Terms Added 2014-03-10

Versartis, Inc. Quote & Chart - Click for current quote - VSAR

About Versartis, Inc. (adapted from Versartis, Inc. prospectus):
They are an endocrine-focused biopharmaceutical company initially developing our novel long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, or GHD, an orphan disease.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "VSAR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.